References and Notes
1a
Schwartz RE.
Hirsch CF.
Sesin DF.
Flor JE.
Chartrain M.
Fromtling RE.
Harris GH.
Salvatore
MJ.
Liesch JM.
Yudin K.
J.
Ind. Microbiol.
1990,
5:
113
1b
Trimurtulu G.
Ohtani I.
Patterson GML.
Moore RE.
Corbett TH.
Valeriote FA.
Demchik L.
J. Am. Chem. Soc.
1994,
116:
4729
1c
Golakoti T.
Ogino J.
Heltzel CE.
Husebo TL.
Jensen CM.
Larsen
LK.
Patterson GML.
Moore RE.
Mooberry SL.
Corbett TH.
Valeriote FA.
J. Am. Chem. Soc.
1995,
117:
12030
1d
Kobayashi M.
Kurosu M.
Ohyabu N.
Wang W.
Fujii S.
Kitagawa I.
Chem. Pharm. Bull.
1994,
42:
2196
1e
Kobayashi M.
Aoki S.
Ohyabu N.
Kurosu M.
Wang W.
Kitagawa I.
Tetrahedron Lett.
1994,
35:
7969
For reviews, see:
1f
Eißler S.
Stončius A.
Nahrwold M.
Sewald N.
Synthesis
2006,
3747
1g
Eggen M.
Georg
GI.
Med. Res.
Rev.
2002,
22:
85
1h
Tius MA.
Tetrahedron
2002,
58:
4343
2a
Al-awar RS.
Corbett TH.
Ray JE.
Polin L.
Kennedy JH.
Wagner MM.
Williams DC.
Mol. Cancer
Ther.
2004,
9:
1061
2b
Smith CD.
Zhang X.
Mooberry SL.
Patterson GM.
Moore RE.
Cancer Res.
1994,
54:
3779
3
Chaganty S.
Golakoti T.
Heltzel C.
Moore RE.
Yoshida WY.
J. Nat. Prod.
2004,
67:
1403
4a
Gardinier KM.
Leahy JW.
J. Org. Chem.
1997,
62:
7098
4b
Liang J.
Moher ED.
Moore RE.
Hoard
DW.
J. Org. Chem.
2000,
65:
3143
4c
Pousset C.
Haddad M.
Larchevêque M.
Tetrahedron
2001,
57:
7163
4d
Li L.-H.
Tius MA.
Org. Lett.
2002,
4:
1637
4e
Mast CA.
Eißler S.
Stončius A.
Stammler H.-G.
Neumann B.
Sewald N.
Chem. Eur.
J.
2005,
11:
4667
5
Eißler S.
Nahrwold M.
Neumann B.
Stammler H.-G.
Sewald N.
Org.
Lett.
2007,
9:
817
6
Kino R.
Daikai K.
Kawanami T.
Furuno H.
Inanaga J.
Org. Biomol.
Chem.
2004,
2:
1822
7
van Horn JD.
Burrows CJ.
Tetrahedron
Lett.
1999,
40:
2069
8a
Wang ZX.
Tu Y.
Frohn M.
Zhang JR.
Shi Y.
J. Am. Chem. Soc.
1997,
119:
11224
8b
Wang ZX.
Tu Y.
Frohn M.
Shi Y.
J. Org. Chem.
1997,
62:
2328
8c
Shi Y.
Acc.
Chem. Res.
2004,
37:
488
8d
Wong OA.
Shi Y.
Chem. Rev.
2008,
108:
3958
9
Hoard DW.
Moher ED.
Martinelli MJ.
Norman
BH.
Org.
Lett.
2002,
4:
1813
10
Ager DJ.
Anderson K.
Oblinger E.
Shi Y.
VanderRoest J.
Org.
Process Res. Dev.
2007,
11:
44
11
Synthesis of (4
R
,5
S
)-4-hydroxy-5-phenyl-tetrahydro-furan-2-one
(5)
trans-Styryl acetic
acid (4, 21.8 mmol, 3.54 g) was dissolved in
MeCN (210 mL). Aqueous KOH soln (1 M, 21.8 mmol, 21.8 mL), acetate
buffer (150 mL, prepared by adding 5.00 mL AcOH to 13.82 g K2CO3 in
1000 mL H2O and pH adjusted to 9.3 by the dropwise addition
of concd aq NaOH soln) and n-Bu4NHSO4 (0.954
mmol, 324 mg) were added. The solution was cooled to 0 ˚C
and Shi catalyst (3, 7.16 mmol, 1.85 g)
was added. Freshly prepared Oxone (29.90 mmol, 18.36 g) in aq Na2EDTA
solution (0.4 mM, 0.0432 mmol, 108 mL) and aq K2CO3 soln
(108 mL, prepared by dissolving 32.00 g K2CO3 in
200 mL H2O) were separately added within 120 min at 0 ˚C.
The cooling bath was removed, and the mixture was stirred for 180
min. Aqueous HCl (6 M, 0.36 mol, 60 mL) was carefully added. The solution
was extracted with Et2O (1 × 600
mL and 2 × 500 mL). The combined organic
layers were washed with sat. aq NaHCO3 solution (200
mL) and brine (30 mL). After drying over Na2SO4 the
solvent was removed in vacuo (40 ˚C) and the crude material
was purified by flash chromatography (hexane-EtOAc 3:2)
giving a crystalline solid (10.78 mmol, 1.920 g, 82% ee),
which was recrystallized from EtOAc (3.5 mL) at 2 ˚C overnight
yielding (4R,5S)-4-hydroxy-5-phenyl-tetrahydrofuran-2-one
(5, 9.58 mmol, 1.708 g, 44%, 90% ee)
as a colorless solid; [α]D
²4 2.57
(c 1.38, CHCl3). HPLC [Chiralpak
AD, 2-PrOH-hexane (1:9), 1 mL/min]: t
R = 16.6
min (5), 12.2 min (ent-5). Anal. Calcd (%) for C10H10O3:
C, 67.41; H, 5.66. Found: C, 67.39; H, 5.67. Further analytical
data are in accordance with ref. 7.
12
General Procedure
for the Synthesis of Substituted
trans
-Styryl Acetic Acids (Table 1, Entries 2 and
3)
KOt-Bu (13 mmol, 1.469
g) in THF (14 mL) was added to a solution of the substituted benzaldehyde
(9 mmol) and
(2-carboxyethyl)triphenylphosphonium bromide
(6 mmol, 2.494 g) in THF (12 mL) at 0 ˚C over
15 min. After stirring for additional 15 min at 0 ˚C
and overnight at r.t., H2O (10 mL) and Et2O
(50 mL) were added. The phases were acidified with 6 M aq HCl soln
to pH 1 and separated. The aqueous phase was extracted with Et2O
(50 mL). The combined organic phases were extracted with sat. aq NaHCO3 soln
(2 × 60 mL). The sat. aq NaHCO3 phases
were washed with EtOAc (3 × 90 mL), acidified
with concd aq HCl to pH 1 and extracted with Et2O (2 × 75
mL). The organic extracts were washed with H2O (20 mL)
and brine (10 mL). After drying over Na2SO4 the
solvent was removed in vacuo (40 ˚C) yielding
the corresponding substituted trans-styryl
acetic acid in 70-74% yield.
13a
Synthesis of (3
R
,4
R
,5
S
)-4-Hydroxy-3-methyl-5-phenyl-tetrahydrofuran-2-one
(6)
Diisopropylamine (11.56 mmol, 1.6 mL) in THF (28
mL) was cooled to -78 ˚C, then n-BuLi (1.6 M in hexane, 11.49 mmol,
7.2 mL) was added dropwise over 15 min. The solution was stirred
for 15 min at -78 ˚C and for 30 min at r.t.
The LDA solution was cooled to -78 ˚C
again and DMPU (34.87 mmol, 4.2 mL) was added. After 45 min lactone
(5, 4.60 mmol, 819 mg) in THF (19.2 mL)
was added during 90 min. After stirring for 45 min and addition
of THF (16 mL), MeI (46.6 mmol, 2.9 mL) in THF (8.6 mL) was added
during 150 min. The solution was stirred overnight at -78 ˚C.
Acetic acid (0.6 mL) in THF (1.0 mL) was added, and the suspension
was warmed to r.t. Then, 5% aq Na2SO3 soln
(8.8 mL) was added, and after 5 min the solvent was removed in vacuo
(40 ˚C), until a pink suspension remained, which
was partitioned between Et2O (40 mL) and H2O
(20 mL). The aqueous layer was extracted with Et2O (4 × 60 mL),
and the combined organic phases were washed with 5% aq
KHSO4 soln (30 mL) and brine (15 mL). After drying over
Na2SO4 the solvent was removed in vacuo (40 ˚C),
and the residue was purified by flash chromatography (hexane-EtOAc,
7:3). The product (3.80 mmol, 731 mg, 90% ee, 85% de)
was recrystallized in EtOAc (1 mL) at -22 ˚C
overnight. A colorless solid (6, 3.00 mmol,
576 mg, 65%, >99% ee, 92% de)
was obtained; [α]D
²4 6.21
(c 1.18, CHCl3); mp 90 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 7.30-7.50
(m, 5 H), 5.06 (d, J = 7.5
Hz, 1 H), 3.98 (m, 1 H), 2.77 (dq, J = 9.4,
6.9 Hz, 1 H), 2.61 (d, J = 5.0
Hz, 1 H), 1.36 (d, J = 6.9
Hz, 3 H). ¹³C NMR (126 MHz, CDCl3): δ = 176.0,
136.6, 128.9, 128.8, 125.7, 84.2, 81.4, 43.6, 12.3. IR (neat): 3409,
3069, 3035, 2974, 2935, 2886, 1732, 1499, 1458, 1363, 1312, 1254,
1184, 1135, 1092, 971, 921, 854, 834, 765, 715, 695, 653 cm-¹.
MS (EI): m/z = 192.1 [M+],
174.1 [M+ - H2O], 107.0 [Ph - CHOH+].
HRMS (EI): m/z calcd for C11H12O3
+ [M+]:
192.07864; found: 192.07934. HPLC [Chiralpak AD, 2-PrOH-hexane
(1:9), 1 mL/min]: t
R = 13.4
min (6), 9.2 min (ent-6). Anal. Calcd (%) for C11H12O3:
C, 68.74; H, 6.29. Found: C, 68.67; H, 6.24.
13b
Chen SY.
Joullie MM.
J.
Org. Chem.
1984,
49:
2168
13c CCDC 703492 contains the
crystallographic data of 6. They can be
obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif.
14
Harcken C.
Brückner R.
Synlett
2001,
718
15
Lee E.
Jeong EJ.
Kang EJ.
Sung LT.
Hong SK.
J.
Am. Chem. Soc.
2001,
123:
10131
16
Tripathy NK.
Georg GI.
Tetrahedron Lett.
2004,
45:
5309
17
Synthesis of (5
S
,6
S
,
E
)-
tert
-Butyl-6-[(4
R
,5
S
)-2,2-dimethyl-5-phenyl-1,3-dioxolan-4-yl]-5-hydroxyhept-2-enoate
(10)
Homoallyl alcohol 9 (0.615
mmol, 170 mg) in CH2Cl2 (0.85 mL) was added
to a solution of Grubbs II catalyst (0.026 mmol, 22.1 mg) and tert-butylacrylate (0.513 mmol, 74.4 µL)
in CH2Cl2 (3.4 mL). The solution was refluxed
in the dark overnight. The solvent was removed in vacuo (30 ˚C), and
the residue was purified by flash chromatography (hexane-EtOAc,
8:2) yielding 10 (0.369 mmol, 138.8 mg, 72%)
as a colorless oil; [α]D
²4 -7.50
(c 1.10, CHCl3). ¹H NMR
(500 MHz, CDCl3): δ = 7.28-7.40
(m, 5 H), 6.77 (m, 1 H), 5.80 (d, J = 15.7
Hz, 1 H), 5.38 (d, J = 7.5
Hz, 1 H), 4.70 (dd, J = 3.8,
7.5 Hz, 1 H), 3.50 (m, 1 H), 2.37 (m, 1 H), 2.22 (m, 1 H), 1.58-1.72
(m, 4 H), 1.41-1.56 (m, 12 H), 0.71 (d, J = 6.9
Hz, 3 H). ¹³C NMR (126 MHz, CDCl3): δ = 165.5,
144.0, 138.0, 128.2, 127.5, 126.6 125.7, 108.2, 80.3, 79.4, 78.1,
73.5, 38.3, 37.4, 28.2, 26.3 24.7, 11.2. IR (neat): 3453, 2979,
2934, 2360, 1709, 1651, 1494, 1454, 1379, 1367, 1326, 1253, 1210,
1086, 1044, 1029, 1006, 980, 917, 879, 850, 730, 700, 647, 512,
466 cm-¹. ESI-MS: m/z = 399.2 [M + Na+].
ESI-HRMS: m/z calcd for C22H32O5Na+ [M + Na+]:
399.21420; found: 399.21373.
18a
Synthesis of (1
S
,2
R
,3
S
,4
S
)-3-Methyl-1-phenylhept-6-ene-1,2,4-triol (11)
A
5% aq HCl soln (4 mL) was added to a solution of homoallyl
alcohol 9 (0.615 mmol, 170.0 mg) in MeOH
(6 mL). After refluxing the solution for 90 min MeOH was removed
in vacuo (40 ˚C), and the aqueous phase was extracted
with Et2O (5 × 30 mL), dried
over MgSO4, and purified by flash chromatography (hexane-EtOAc,
7:3). A colorless crystalline solid (11,
0.405 mmol, 95.7 mg, 66%) was obtained; [α]D
²4 43.59
(c 1.22, CHCl3); mp 77 ˚C. ¹H NMR
(500 MHz, CDCl3): δ = 7.26-7.49
(m, 5 H), 5.80 (m, 1 H), 5.13-5.20 (m, 2 H), 4.70 (δ, J = 7.5 Hz,
1 H), 4.15 (d, J = 7.5
Hz, 1 H), 3.70 (m, 1 H), 2.60 (d, J = 2.5
Hz, 1 H), 2.27-2.44 (m, 3 H), 2.21 (s, 1 H), 1.98 (m, 1
H), 1.16 (d, J = 6.9
Hz, 3 H). ¹³C NMR (126 MHz, CDCl3): δ = 141.8, 134.8,
128.6, 128.1, 126.8, 118.4, 75.1 75.0, 74.1, 40.0, 37.2, 11.2. IR
(neat): 3545, 3345, 3063, 3030, 2970, 2923, 2360, 2341, 1639, 1493,
1455, 1431, 1404, 1382, 1340, 1269, 1212, 1135, 1071, 1023, 1000,
989, 974, 917, 870, 842, 786, 697, 639, 604, 544, 475, 419 cm-¹.
ESI-MS: m/z = 259.2 [M + Na+].
ESI-HRMS: m/z calcd for C14H20O3Na+ [M + Na+] 259.13047;
found: 259.13030. Anal. Calcd (%) for C14H20O3:
C, 71.16; H, 8.53. Found: C, 71.00; H, 8.60.
18b CCDC 703493 contains
the crystallographic data of 11. They can
be obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif.